BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25313527)

  • 1. Peptide conjugation: before or after nanoparticle formation?
    Valetti S; Mura S; Noiray M; Arpicco S; Dosio F; Vergnaud J; Desmaële D; Stella B; Couvreur P
    Bioconjug Chem; 2014 Nov; 25(11):1971-83. PubMed ID: 25313527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor.
    Valetti S; Maione F; Mura S; Stella B; Desmaële D; Noiray M; Vergnaud J; Vauthier C; Cattel L; Giraudo E; Couvreur P
    J Control Release; 2014 Oct; 192():29-39. PubMed ID: 24984010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Gemcitabine Conjugated Albumin Nanoparticles: a Potential Strategy to Enhance Drug Efficacy in Pancreatic Cancer Treatment.
    Kushwah V; Agrawal AK; Dora CP; Mallinson D; Lamprou DA; Gupta RC; Jain S
    Pharm Res; 2017 Nov; 34(11):2295-2311. PubMed ID: 28795274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
    Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
    Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Delivery System of RGD-HSA Loaded GEM/CUR Nanoparticles for the Treatment of Pancreatic Cancer Therapy.
    Ma T; Jiang JL; Qi WX; Chen JY; Xu HP
    Drug Des Devel Ther; 2022; 16():2395-2406. PubMed ID: 35923931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
    Yin N; Yu H; Zhang X; Lv X
    Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
    Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
    J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment.
    Zhang J; Zhang P; Zou Q; Li X; Fu J; Luo Y; Liang X; Jin Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30405089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
    Arias JL; Reddy LH; Couvreur P
    Langmuir; 2008 Jul; 24(14):7512-9. PubMed ID: 18540685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin-human serum albumin nanoparticles decorated with PDL1 binding peptide for targeting PDL1-expressing breast cancer cells.
    Hasanpoor Z; Mostafaie A; Nikokar I; Hassan ZM
    Int J Biol Macromol; 2020 Sep; 159():137-153. PubMed ID: 32335119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management.
    Kushwah V; Katiyar SS; Dora CP; Kumar Agrawal A; Lamprou DA; Gupta RC; Jain S
    Acta Biomater; 2018 Jun; 73():424-436. PubMed ID: 29649635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of folic acid-conjugated chitosan nanoparticles for targeted and controlled delivery of gemcitabinein lung cancer therapeutics.
    Wang F; Wang Y; Ma Q; Cao Y; Yu B
    Artif Cells Nanomed Biotechnol; 2017 Dec; 45(8):1530-1538. PubMed ID: 27894196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
    Khare V; Singh A; Mahajan G; Alam N; Kour S; Gupta M; Kumar A; Singh G; Singh SK; Saxena AK; Mondhe DM; Gupta PN
    Eur J Pharm Sci; 2016 Sep; 92():183-93. PubMed ID: 27404580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine cationic polymeric nanoparticles against ovarian cancer: formulation, characterization, and targeted drug delivery.
    Bhattacharya S; Anjum MM; Patel KK
    Drug Deliv; 2022 Dec; 29(1):1060-1074. PubMed ID: 35363113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy for the treatment of pancreatic cancer through hyaluronic acid-decorated nanoparticles loaded with quercetin and gemcitabine: A preliminary in vitro study.
    Serri C; Quagliariello V; Iaffaioli RV; Fusco S; Botti G; Mayol L; Biondi M
    J Cell Physiol; 2019 Apr; 234(4):4959-4969. PubMed ID: 30334571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of nanoparticles for the delivery of gemcitabine hydrochloride.
    Khaira R; Sharma J; Saini V
    ScientificWorldJournal; 2014; 2014():560962. PubMed ID: 24592173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment.
    Han H; Wang J; Chen T; Yin L; Jin Q; Ji J
    J Colloid Interface Sci; 2017 Dec; 507():217-224. PubMed ID: 28800445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line.
    Yu X; Song Y; Di Y; He H; Fu D; Jin C
    Sci Rep; 2016 Aug; 6():31539. PubMed ID: 27515795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.
    Jiang T; Yu X; Carbone EJ; Nelson C; Kan HM; Lo KW
    Int J Pharm; 2014 Nov; 475(1-2):547-57. PubMed ID: 25194353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.